世界卫生组织及全球卫生伙伴通过ACT加速器宣布一项全球合作协议，将在6个月内向低收入和中等收入国家提供1.2亿份COVID-19快速抗原检测试剂1。比尔及梅琳达·盖茨基金会与Abbott和SD Biosensor达成协议，这些检测试剂的供应价格最高为每单位5美元1。全球基金初期拨款5000万美元用于采购这些试剂1。
这些快速检测试剂可在15-30分钟内出结果，旨在帮助缺乏实验室设施和专业人员的国家扩大检测能力1。Unitaid和Africa CDC将从2020年10月开始在非洲20个国家推出该项目1。WHO主任Tedros Adhanom Ghebreyesus表示："高质量快速检测向我们展示病毒躲在哪里，这是快速追踪和隔离接触者、切断传播链的关键"1。盖茨基金会首席执行官Mark Suzman指出："检测是对抗COVID-19的必要工具，我们很高兴加入这一伙伴关系，以确保最新的、高质量的诊断不仅提供给出价最高的国家，而是以承受得起的价格提供给世界上收入较低的国家"1。
该合作是ACT-Accelerator诊断支柱更广泛目标的一部分，该支柱目标是在12个月内向低收入和中等收入国家供应5亿份检测试剂1。
The World Health Organization and global health partners announced a collaborative initiative to supply 120 million affordable COVID-19 rapid antigen tests to low- and middle-income countries through the ACT-Accelerator framework 1. Under the agreement, Abbott and SD Biosensor will provide these diagnostic kits at a maximum price of $5 per unit, with the Global Fund committing an initial $50 million in procurement funding 1. The rapid tests deliver results within 15 to 30 minutes, enabling countries lacking laboratory infrastructure and specialized personnel to expand their testing capacity 1.
Unitaid and the Africa CDC will launch the rollout across 20 African nations beginning in October 2020 1. WHO Director-General Tedros Adhanom Ghebreyesus emphasized that "quality rapid tests show us where the virus is hiding, and this is essential for rapid case finding and isolation of contacts to break chains of transmission" 1. The Bill & Melinda Gates Foundation's Chief Executive Officer Mark Suzman added that "testing is a necessary tool in the fight against COVID-19, and we are pleased to join this partnership to ensure that cutting-edge, quality diagnostics are not only available to the highest bidders but are provided at affordable prices to lower-income countries around the world" 1.
This initiative aligns with the broader ACT-Accelerator diagnostics pillar, which aims to deliver 500 million tests to low- and middle-income countries within 12 months 1.
评论
还没有评论，欢迎留下第一条。